Suppr超能文献

使用四轴运动体模研究 VMAT SBRT 的相互作用效应。

A study of the interplay effect for VMAT SBRT using a four-axes motion phantom.

机构信息

INSERM, Toulouse, France.

IUCT-Oncopole, Toulouse, France.

出版信息

J Appl Clin Med Phys. 2020 Aug;21(8):208-215. doi: 10.1002/acm2.12947. Epub 2020 Jun 23.

Abstract

PURPOSE

To assess the accuracy of volumetric modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) when treating moving targets (such as lung or liver lesions), focusing on the impact of the interplay effect in the event of complex breathing motion and when a gating window is used.

METHODS

A dedicated programmable motion platform was implemented. This platform can carry large quality assurance (QA) phantoms and achieve complex three-dimensional (3D) motion. Volumetric modulated arc therapy SBRT plans were delivered with TrueBeam linac to this moving setup and the measured dose was compared to the computed one. Several parameters were assessed such as breathing period, dose rate, dose prescription, shape of the breathing pattern, the use of a planning target volume (PTV) margin, and the use of a gating window.

RESULTS

Loss of dose coverage (D95%) was acceptable in most situations. The doses received by 95% of the CTV, D95% ( ) ranged from 94 to 101% (mean 98%) and the doses received by 2% of the CTV D2% ( ) ranged from 94% to 110% of the prescribed dose. A visible interplay effect was observed when no margin was used or when the number of breathing cycles during the treatment delivery was lower than 20.

CONCLUSIONS

In our clinical context, treating lung and liver lesions using VMAT SBRT is reasonable. The interplay effect was moderated and acceptable in all simulated situations.

摘要

目的

评估容积旋转调强放疗(VMAT)立体定向体部放疗(SBRT)治疗移动靶区(如肺部或肝脏病变)的准确性,重点关注在复杂呼吸运动和使用门控窗的情况下,相互作用效应对治疗的影响。

方法

采用专用可编程运动平台。该平台可以携带大型质量保证(QA)体模并实现复杂的三维(3D)运动。使用 TrueBeam 直线加速器将容积旋转调强放疗 SBRT 计划输送到这个运动系统中,并将测量的剂量与计算的剂量进行比较。评估了几个参数,如呼吸周期、剂量率、剂量处方、呼吸模式的形状、是否使用计划靶区(PTV)边界以及是否使用门控窗。

结果

在大多数情况下,剂量覆盖(D95%)的损失是可以接受的。CTV 的 95%( )接受的剂量范围为 94%至 101%(平均值为 98%),CTV 的 2%( )接受的剂量范围为 94%至 110%的处方剂量。当不使用边界或在治疗输送过程中的呼吸周期数少于 20 个时,观察到明显的相互作用效应。

结论

在我们的临床环境中,使用 VMAT SBRT 治疗肺部和肝脏病变是合理的。在所有模拟情况下,相互作用效应得到了缓解和控制,在可接受的范围内。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a28/7484847/70f58bf31a50/ACM2-21-208-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验